OVERVIEW

Movement Beyond Laxatives: Evolving Pharmacologic Options for IBS-C and CIC is organized by PharmCon, Inc. and will be held from Jul 15, 2018 - May 17, 2021.

Credits : 1 Contact Hour(s)

Conference Description :
IBS-C and CIC are highly prevalent conditions that negatively impact Quality of Life and pose a significant economic burden on the healthcare system. Because so many patients self-treat the conditions, estimates of the number of Americans that suffer from IBS-C and CIC vary widely ranging from 2% to 27% of the population. Despite the $400 million dollars that are spent on laxatives each year, constipation still accounts for 2.5 million physician visits annually in the U.S. revealing a desperate need for improved patient counseling and knowledge of pharmacologic options beyond laxatives in pharmacies around the nation where millions of patients seek pharmacist recommendations. When traditional treatments, such as dietary manipulation and standard laxatives do not adequately treat or fail to treat IBS-C and CIC, pharmacists must be prepared to educate patients regarding the pharmacologic options available to relieve these frustrating and costly conditions.

Conference Objectives are :
Nurse
• Outline etiology and epidemiology of IBS-C and CIC in the U.S.
• Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
• Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.

Pharmacist
• Outline etiology and epidemiology of IBS-C and CIC in the U.S.
• Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
• Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.

Pharmacy Technician
• Identify common causes of IBS-C and CIC in the U.S.
• Identify FDA approved pharmacologic treatment options for IBS-C and CIC
• Recognize effective patient communication skills with the physician.